Erschienen in:
06.09.2018 | What's New in Intensive Care
What’s new on emerging resistant Candida species
verfasst von:
Andrea Cortegiani, Giovanni Misseri, Anuradha Chowdhary
Erschienen in:
Intensive Care Medicine
|
Ausgabe 4/2019
Einloggen, um Zugang zu erhalten
Excerpt
Accounting for more than 400,000 annual cases worldwide, with an incidence from 0.24 to 34.3 patients/1000 ICU admissions and mortality that approaches 40%,
Candida spp. constitute the third or fourth most common cause of healthcare-related infections worldwide [
1]. Although
C. albicans remains the main causative pathogen, the increasing isolations of
non-
albicans Candida spp. resistant to first- and second-line antifungals (namely, fluconazole and echinocandins) in nosocomial infections is concerning. Resistance to azoles remains uncommon in
C. albicans (< 5%), but it is more prevalent in
C. glabrata (4–16%),
C. parapsilosis (4–10%), and
C. tropicalis (4–9%) [
2]. Acquired resistance following echinocandin exposure appears to be on the rise, and the emergence of multi-resistant species among
Candida glabrata and the novel pathogen
Candida auris poses a serious threat to critically ill patients. …
